Video
Marco Caspani, Chief Executive Officer at CSL Srl, discussed the challenges and the opportunity of producing anaerobic bacteria during the press conference on The Akkermansia Company.
Michael Oredsson, CEO at The Akkermansia Company, discussed with the new postbiotic supplement containing pastorised Akkermansia muciniphila.
Stijn Oste, Vice president Metagenics, head EMEA, presents the new supplement during the press conference held in Milan (Italy).
Denise Kelly (Investment Advisor at Seventure) discussed the next challenges and opportunities in the field of gut microbiome therapeutics.
Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.
Sarah Lebeer (Research professor, University of Antwerp) described how she and her colleagues developed a new probiotic topic formulation to treat Acne.
Holger Lenz discusses the interest of Bayer in the microbiome space during Microbiome Connect: Europe 2022.
Maria Teresa Abreu (University of Miami, USA) discussed some new strategies to design clinical trials.
Theresa Pizarro, (Case Western Reserve University School of Medicine) discussed the roles of epithelial barrier’s cytokines, gut microbiome and Gasdermin in IBD patients.
